Today Probiodrug announced the results from a combination study of its lead Phase IIa product, glutaminylcyclase-inhibitor PQ912, and its specific monoclonal antibody PBD-C06, the company’s second asset in preclinical stage. This is the first preclinical proof-of-concept data and showed an additive effect of this two-pronged approach of inhibiting the formation and increasing the clearance of pyro-glutamyl-Amyloid beta (pGlu-Abeta), the toxic version of amyloid beta, potentially a key p
13 Sep 2016
Combo trial data may boost early R&D
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Combo trial data may boost early R&D
Vivoryon Therapeutics N.V. (VVY:AMS) | 0 0 0.0%
- Published:
13 Sep 2016 -
Author:
Dr Jonas Peciulis -
Pages:
3
Today Probiodrug announced the results from a combination study of its lead Phase IIa product, glutaminylcyclase-inhibitor PQ912, and its specific monoclonal antibody PBD-C06, the company’s second asset in preclinical stage. This is the first preclinical proof-of-concept data and showed an additive effect of this two-pronged approach of inhibiting the formation and increasing the clearance of pyro-glutamyl-Amyloid beta (pGlu-Abeta), the toxic version of amyloid beta, potentially a key p